Akeso Deepens Cadonilimab Story With Survival Data And Global GBM Trial [Yahoo! Finance]
Merck & Company, Inc. (new) (MRK)
Last merck & company, inc. (new) earnings: 4/28 06:45 am
Check Earnings Report
US:NYSE Investor Relations:
investors.merck.com/home/default.aspx
Company Research
Source: Yahoo! Finance
Akeso (SEHK:9926) reported long term survival data from a Phase II study of cadonilimab in advanced cervical cancer, highlighting durable benefits in a setting with limited treatment options. The company also entered a global clinical collaboration with INOVIO and major cancer centers to test cadonilimab combination therapy in glioblastoma. Akeso shares last closed at HK$102.0, with the stock up 41.9% over the past year and 156.9% over three years, while return year to date is a 10.0% decline. In that context, the latest data readout and the new collaboration help frame how the market may be weighing both the risks and the potential of cadonilimab within the company's broader pipeline. For investors, the key questions now are how these cervical cancer and glioblastoma programs might shape Akeso's future portfolio mix and its ability to reach more global markets. The new trial and the long term survival analysis provide additional clinical datapoints to watch, particularly as re
Show less
Read more
Impact Snapshot
Event Time:
MRK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MRK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MRK alerts
High impacting Merck & Company, Inc. (new) news events
Weekly update
A roundup of the hottest topics
MRK
News
- Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? [Yahoo! Finance]Yahoo! Finance
- Evaxion announces business update and full year 2025 financial results [Yahoo! Finance]Yahoo! Finance
- Assessing Merck (MRK) Valuation As Recent Share Price Strength Meets Conflicting Fair Value Views [Yahoo! Finance]Yahoo! Finance
- Merck's KEYTRUDA Combo Wins and Pipeline Shuffle Might Change The Case For Investing In Merck (MRK) [Yahoo! Finance]Yahoo! Finance
- ???????:???????????2035????411.8?????????? ? ???????????????? [CNET News]CNET News
MRK
Earnings
- 2/3/26 - Beat
MRK
Sec Filings
- 2/24/26 - Form 10-K
- 2/17/26 - Form 13F-HR
- 2/13/26 - Form 144/A
- MRK's page on the SEC website